Floatz logo

Ursodeoxycholic Acid

Cholestasis

Assistance Publique - Hôpitaux de ParisSmall moleculePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Cholestasis cohort.

Asset / SponsorPhaseRating
Linerixibat
GlaxoSmithKline
Phase 3BB
Maralixibat
Mirum Pharmaceuticals, Inc.
Phase 3BB
Gabapentin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3B
Tauroursodeoxycholic
Beijing Trendful Kangjian Medical Information Consulting Limited Company
Phase 3B
2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID
Assistance Publique - Hôpitaux de Paris
Phase 3B

View all 24 →

Same molecule, other indications

Ursodeoxycholic Acid is also rated in:

primary biliary cholangitisActive
A
Indicative · Phase 4
82 / 100
View asset →
cirrhosis of liverActive
BBB
Indicative · Phase 3
72 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →